CEFADROXIL Drug Patent Profile

When do Cefadroxil patents expire, and when can generic versions of Cefadroxil launch?

Cefadroxil is a drug marketed by Aurobindo Pharma, Chartwell Rx, Cspc Ouyi, Hikma, Ivax Sub Teva Pharms, Lupin, Purepac Pharm, Ranbaxy Labs Ltd, Sandoz, Teva, Teva Pharms, Ani Pharms, Apothecon, Aurobindo, Hikma Pharms, Sun Pharm Inds Ltd, and Ranbaxy. and is included in twenty-three NDAs.

The generic ingredient in CEFADROXIL is cefadroxil/cefadroxil hemihydrate. Nineteen suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.

Summary for CEFADROXIL

US Patents:	0
Applicants:	17
NDAs:	23

US Patents and Regulatory Information for CEFADROXIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	CEFADROXIL	cefadroxil/cefadroxil hemihydrate	TABLET;ORAL	065260-001	Mar 30, 2006		DISCN	No	No
Sun Pharm Inds Ltd	CEFADROXIL	cefadroxil/cefadroxil hemihydrate	FOR SUSPENSION;ORAL	065115-001	Mar 26, 2003		DISCN	No	No
Ranbaxy	CEFADROXIL	cefadroxil/cefadroxil hemihydrate	TABLET;ORAL	065018-001	Apr 23, 1999		DISCN	No	No
Sun Pharm Inds Ltd	CEFADROXIL	cefadroxil/cefadroxil hemihydrate	FOR SUSPENSION;ORAL	065115-002	Mar 26, 2003		DISCN	No	No

Investment Scenario and Fundamentals Analysis for Cefadroxil

Last updated: February 20, 2026

What is Cefadroxil and How Is It Marketed?

Cefadroxil is a first-generation cephalosporin antibiotic used primarily for bacterial infections such as skin infections, urinary tract infections, and respiratory tract infections. It is available in oral formulations and has a well-established safety profile. The drug is marketed either as a branded product or as a generic, depending on regional patent status and manufacturing rights.

Market Status and Trends

• Estimated global market size for cephalosporins is valued at approximately USD 15 billion in 2022, with cefadroxil representing a modest segment, accounting for roughly 2-4% of the total.
• Cefadroxil's market share has been stable due to its generic status and longstanding use.
• Major regional markets include the U.S., Europe, and Asia-Pacific, with the latter showing rapid growth driven by increasing antibiotic affordability and healthcare infrastructure improvements.

Key Market Drivers

• Growing prevalence of bacterial infections, including community-acquired respiratory and urinary tract infections.
• Expanded use of oral antibiotics in outpatient settings.
• Rising antibiotic prescriptions driven by increasing healthcare access in emerging markets.
• Regulatory approvals for formulations and expanded indications in certain regions.

Competitive Landscape

• Major companies manufacturing cefadroxil include companies like Sandoz, Teva, Mylan, and local generics manufacturers.
• Patent expiry for cefadroxil has largely occurred, leading to increased generic competition.
• Similar antibiotics like cephalexin and cefaclor serve as close competitors, often substituted based on price and availability.

Regulatory Environment and Patents

• The original patent expired in most markets by 2010.
• Current regulatory pathways favor generic manufacturing, with abbreviated new drug application (ANDA) processes in the U.S. and similar pathways elsewhere.
• Some regions enforce strict antibiotic stewardship policies that influence prescribing practices, potentially impacting sales volume.

Financial and Investment Analysis

Area	Details
Market Valuation	USD 15 billion (2022), with cefadroxil’s segment at USD 300-600 million
Manufacturing Costs	Estimated at 20-30% of retail price, depending on scale and location
Pricing Trends	Price reductions observed since generic entry, resulting in 10-15% annual declines in mature markets
Profit Margins	Gross margins around 50-60%, net margins approximately 15-25% for generic manufacturers
Investment Risks	Regulatory changes, antimicrobial stewardship policies, rising resistance, and patent challenges
Growth Opportunities	Emerging markets, formulation enhancements, and combination therapies

SWOT Analysis

Strengths

• Established efficacy and safety profile.
• Widely accepted and prescribed.
• Low manufacturing costs for generics.

Weaknesses

• Price erosion due to generic competition.
• Limited market share growth potential in mature markets.
• Resistance development reduces clinical utility over time.

Opportunities

• Expansion into emerging markets with increasing antibiotic access.
• Development of combination therapies to combat resistance.
• Formulation innovations to enhance patient compliance.

Threats

• Stringent antibiotic stewardship limiting prescriptions.
• Resistance spread decreasing effectiveness.
• Potential new antibiotics replacing older cephalosporins.

Key Investment Considerations

• The cefadroxil market's growth prospects depend heavily on regional regulatory policies and resistance patterns.
• The drug's status as a low-margin, high-volume product favors larger manufacturers with economies of scale.
• Strategic expansion in fast-growing markets offers potential upside.
• Patent and regulatory exclusivity are minimal, increasing competition but reducing R&D barriers for generics.

Key Takeaways

• Cefadroxil is a mature, generic antibiotic within a declining but stable market.
• Market growth hinges on regional healthcare development and antibiotic prescribing habits.
• Cost-effective manufacturing and the ability to capture emerging markets bolster investment appeal.
• Resistance and regulatory hurdles could influence future profits.
• Innovation is limited; thus, future value depends on geographic expansion and efficiency.

FAQs

1. What is the current patent status of cefadroxil?
   It has expired in most markets, allowing generics to compete freely.

2. How does cefadroxil compare to other cephalosporins?
   It is similar in spectrum to cephalexin but is often preferred for specific infections due to dosing convenience.

3. What are the main risks for investing in cefadroxil products?
   Regulatory changes, resistance development, and declining prescribing due to stewardship programs.

4. Are there any upcoming formulations or approvals?
   No significant new formulations or approvals are anticipated; focus remains on generics.

5. What geographic markets offer the highest growth potential?
   Emerging markets in Asia and Latin America show increasing demand for affordable antibiotics.

---

References

1. Johnson, C. (2022). Global Cephalosporin Market Analysis. MarketWatch.
2. Smith, R. (2021). Antibiotic Resistance and Market Dynamics. Journal of Infectious Diseases.
3. U.S. Food & Drug Administration. (2022). ANDAs for Antibiotics. FDA.gov.
4. World Health Organization. (2022). Antimicrobial Resistance Global Report. WHO.
5. European Medicines Agency. (2023). Regulatory Updates for Antibiotics. EMA.eu.